Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Real-life experiences with goal-directed prohemostatic therapy with fibrinogen concentrate, prothrombin complex concentrate, and recombinant factor VIIa: a retrospective study of 287 consecutive patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Reference serum percentile values of adiponectin, leptin, and adiponectin/leptin ratio in healthy Danish children and adolescents

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Managing patients on direct factor Xa inhibitors with rapid thrombelastography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Quantification of biotin in plasma samples by column switching liquid chromatography - tandem mass spectrometry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. An explorative metabolomic analysis of the endothelium in pulmonary hypertension

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Intervening on the storage time of RBC units and its effects on adverse recipient outcomes using real-world data

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exploratory Investigation of the Plasma Proteome Associated with the Endotheliopathy of Trauma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The Danish Capital Region Blood Bank operates a 24/7 on-call service staffed with physicians specialized in hemostatic management to guide clinicians in hemostatic resuscitation, including administration of prohemostatic therapy (PHT). The outcome of patients who receive PHT as part of hemostatic resuscitation remains unanswered. The objective of this study was therefore to investigate clinical outcome of patients receiving PHT managed by the on-call service. We identified 287 patients who received PHT during 2015-16, of which 161 (59%) received fibrinogen concentrate (FC), 111 (39%) received prothrombin complex concentrate (PCC), and 15 (5%) received recombinant factor VIIa (rFVIIa) as the first product. Patients were critically ill with a 30-day mortality of 31%. Among FC recipients, cardiothoracic admission, non-trauma, and antithrombotics predicted survival. FC recipients had lower platelet count and thrombelastography clot strengths than the other PHT groups and within the group, these factors predicted mortality. The symptomatic thromboembolic event (TE) rate at 30 days was 5%. For PCC recipients, vitamin K antagonists predicted survival, while rivaroxaban predicted mortality. TE rate was 2%. We did not identify factors associated with survival in the small group of rFVIIa recipients. TE rate was 13%. In summary, trauma and coagulopathy predicted mortality in patients who received FC and our data suggest that optimization of PHT algorithms may be possible. Outcome of patients who received PCC was comparable to results reported elsewhere and its use may be safe in a setting as reported here. Recombinant FVIIa was rarely used but had the highest incidence of arterial thromboembolism.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Clinical and Laboratory Investigation
Vol/bind82
Udgave nummer2
Sider (fra-til)156-161
Antal sider6
ISSN0036-5513
DOI
StatusUdgivet - apr. 2022

ID: 74724211